Nothing Special   »   [go: up one dir, main page]

CY1115826T1 - Μεσα για τη θεραπεια διαταραχων οι οποιες εμπλεκουν τη ρυθμιση των υποδοχεων ρυανοδινης - Google Patents

Μεσα για τη θεραπεια διαταραχων οι οποιες εμπλεκουν τη ρυθμιση των υποδοχεων ρυανοδινης

Info

Publication number
CY1115826T1
CY1115826T1 CY20141101052T CY141101052T CY1115826T1 CY 1115826 T1 CY1115826 T1 CY 1115826T1 CY 20141101052 T CY20141101052 T CY 20141101052T CY 141101052 T CY141101052 T CY 141101052T CY 1115826 T1 CY1115826 T1 CY 1115826T1
Authority
CY
Cyprus
Prior art keywords
instruments
regulation
diseases
disorder treatment
treatment
Prior art date
Application number
CY20141101052T
Other languages
English (en)
Inventor
Jiaming Yan
Sandro Belvedere
Yael Webb
Marc Bertrand
Nicole Villeneuve
Original Assignee
Les Laboratoires Servier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Les Laboratoires Servier filed Critical Les Laboratoires Servier
Publication of CY1115826T1 publication Critical patent/CY1115826T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/36—Seven-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/841—Muscles; heart

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται σε παράγωγα της 1,4-βενζοθειαζεπίνης και στη χρήση τους για τη θεραπεία παθήσεων, διαταραχών και νόσων οι οποίες συνδέονται με τους υποδοχείς ρυανοδίνης (RyRs) οι οποίοι ρυθμίζουν τη λειτουργία του διαύλου ασβεστίου στα κύτταρα. Η εφεύρεση αποκαλύπτει επίσης φαρμακευτικές συνθέσεις οι οποίες περιέχουν αυτές τις ενώσεις και τις χρήσεις τους για τη θεραπεία νόσων και παθήσεων που συνδέονται με τους RyRs, συγκεκριμένα διαταραχών του καρδιακού, μυοσκελετικού και κεντρικού νευρικού συστήματος (ΚΝΣ).
CY20141101052T 2012-04-18 2014-12-17 Μεσα για τη θεραπεια διαταραχων οι οποιες εμπλεκουν τη ρυθμιση των υποδοχεων ρυανοδινης CY1115826T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261625890P 2012-04-18 2012-04-18
EP12167732.2A EP2708535A1 (en) 2012-05-11 2012-05-11 Agents for treating disorders involving modulation of ryanodine receptors
EP20130164051 EP2653466B1 (en) 2012-04-18 2013-04-17 Agents for treating disorders involving modulation of ryanodine receptors

Publications (1)

Publication Number Publication Date
CY1115826T1 true CY1115826T1 (el) 2017-01-25

Family

ID=49165460

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141101052T CY1115826T1 (el) 2012-04-18 2014-12-17 Μεσα για τη θεραπεια διαταραχων οι οποιες εμπλεκουν τη ρυθμιση των υποδοχεων ρυανοδινης

Country Status (48)

Country Link
US (3) US20130281512A1 (el)
EP (2) EP2708535A1 (el)
JP (1) JP5965542B2 (el)
KR (1) KR101731459B1 (el)
CN (1) CN104350045B (el)
AP (1) AP3591A (el)
AR (1) AR090712A1 (el)
AU (1) AU2013248313B2 (el)
BR (1) BR112014025670B1 (el)
CA (1) CA2870599C (el)
CL (1) CL2014002756A1 (el)
CO (1) CO7091184A2 (el)
CR (1) CR20140476A (el)
CU (1) CU24327B1 (el)
CY (1) CY1115826T1 (el)
DK (1) DK2653466T3 (el)
DO (1) DOP2014000230A (el)
EA (1) EA027922B1 (el)
EC (1) ECSP14027564A (el)
ES (1) ES2529890T3 (el)
GT (1) GT201400222A (el)
HK (2) HK1192537A1 (el)
HR (1) HRP20141113T8 (el)
HU (1) HUE024284T2 (el)
IL (1) IL235043A (el)
JO (1) JO3070B1 (el)
MA (1) MA37525B1 (el)
MD (1) MD4489C1 (el)
ME (1) ME01969B (el)
MX (1) MX350890B (el)
MY (1) MY167783A (el)
NI (1) NI201400123A (el)
NZ (1) NZ701122A (el)
PE (1) PE20142193A1 (el)
PH (1) PH12014502256A1 (el)
PL (1) PL2653466T3 (el)
PT (1) PT2653466E (el)
RS (1) RS53711B1 (el)
RU (1) RU2644350C2 (el)
SA (1) SA113340479B1 (el)
SG (1) SG11201406404YA (el)
SI (1) SI2653466T1 (el)
TN (1) TN2014000424A1 (el)
TW (1) TWI507399B (el)
UA (1) UA113759C2 (el)
UY (1) UY34742A (el)
WO (1) WO2013156505A1 (el)
ZA (1) ZA201407499B (el)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2906168C (en) 2013-03-15 2018-07-24 Rosalind Franklin University Of Medicine And Science Compounds for stabilizing ryanodine receptors from aberrant levels of calcium release
US9725429B2 (en) 2013-03-15 2017-08-08 Rosalind Franklin University Of Medicine And Science Furanyl-imine and thiofuranyl-imine compounds for stabilizing ryanodine receptors from aberrant levels of calcium release
ES2934319T3 (es) 2013-07-18 2023-02-21 Baylor College Medicine Métodos y composiciones para el tratamiento de la atrofia muscular, la debilidad muscular y/o la caquexia
WO2015197562A1 (en) * 2014-06-23 2015-12-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of disorders or diseases associated with ryanodine receptor dysfunction
US10071996B2 (en) 2014-07-30 2018-09-11 Aetas Pharma Co., Ltd. Optical isomer of 1,4-benzothiazepine-1-oxide derivative, and pharmaceutical composition prepared using same
AU2015374155A1 (en) * 2014-12-30 2017-07-20 Myotherix, Inc. Novel calcium modulators
ES2643856B1 (es) 2016-05-24 2018-08-03 Universidad Del Pais Vasco / Euskal Herriko Unibertsitatea Triazoles para la regulación de la homeostasis de calcio intracelular
US11426415B2 (en) 2017-03-06 2022-08-30 Washington University Treatment for Wolfram syndrome and other endoplasmic reticulum stress disorders
JP7282332B2 (ja) * 2017-10-25 2023-05-29 学校法人順天堂 リアノジン受容体阻害薬
US11026905B2 (en) 2018-04-19 2021-06-08 Tvardi Therapeutics, Inc. STAT3 inhibitors
WO2019204614A1 (en) 2018-04-19 2019-10-24 Tvardi, Inc. Stat3 inhibitors
BR112022014660A2 (pt) 2020-01-24 2022-09-13 Tvardi Therapeutics Inc Compostos terapêuticos, formulações e usos dos mesmos
JP2023548342A (ja) * 2020-11-06 2023-11-16 サイトキネティックス， インコーポレイテッド 二環式１，４－ジアゼパノン及びその治療的使用
CN116887839A (zh) 2021-01-08 2023-10-13 阿姆果制药有限公司 兰诺定受体调节剂的结晶形式及其用途
WO2022246114A2 (en) * 2021-05-20 2022-11-24 Armgo Pharma, Inc. Pharmaceutical compositions comprising a ryanodine receptor modulator and uses thereof
JP2024539735A (ja) * 2021-11-16 2024-10-29 アームゴ・ファーマ・インコーポレーテッド 治療用化合物
EP4230196A1 (en) 2022-02-21 2023-08-23 Som Innovation Biotech, S.A. Compounds for use in the treatment of dystrophinopathies
WO2023244946A1 (en) 2022-06-15 2023-12-21 Tvardi Therapeutics, Inc. Prodrugs of stat3 inhibitors

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE58901634D1 (de) 1988-11-05 1992-07-16 Bayer Ag Verfahren zur kernchlorierung von aromatischen kohlenwasserstoffen.
GB9021813D0 (en) * 1990-10-08 1990-11-21 Ici Plc Tricyclic heterocycles
JP3497164B2 (ja) 1991-06-28 2004-02-16 スミスクライン・ビーチャム・コーポレイション 二環式フィブリノーゲン拮抗薬
UA41342C2 (uk) * 1992-11-09 2001-09-17 Дзе Бутс Компані Плс 2,3,4,5-тетрагідро-1,4-бензотіазепіни, їх стереоізомери або їх фармацевтично прийнятні солі, спосіб їх одержання та фармацевтична композиція на їх основі
FR2752017B1 (fr) 1996-08-01 1998-10-16 Hispano Suiza Sa Inverseur de poussee de turboreacteur a portes formant ecopes
GB9914745D0 (en) 1999-06-24 1999-08-25 Knoll Ag Therapeutic agents
US7718644B2 (en) * 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US8022058B2 (en) * 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US20040229781A1 (en) * 2000-05-10 2004-11-18 Marks Andrew Robert Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias
US7879840B2 (en) * 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US20020183307A1 (en) 2000-07-26 2002-12-05 Tremont Samuel J. Novel 1,4-benzothiazephine and 1,5-benzothiazepine compounds as inhibitors of apical sodium co-dependent bile acid transport and taurocholate uptake
AU2002224797B2 (en) 2000-10-30 2006-10-26 Janssen Pharmaceutica N.V. Tripeptidyl peptidase inhibitors
US7544678B2 (en) 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
AU2004220548A1 (en) 2003-03-07 2004-09-23 The Trustees Of Columbia University, In The City Of New York Type 1 ryanodine receptor-based methods
US20090292119A1 (en) * 2003-10-07 2009-11-26 The Trustees Of Columbia University In The City Of New York Methods for synthesizing benzothiazepine compounds
DE112005003511T5 (de) 2005-03-23 2008-04-17 Battelle Memorial Institute, Richland RFID-System mit verbesserter Leistungsfähigkeit
US7704990B2 (en) 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
WO2007127145A2 (en) 2006-04-25 2007-11-08 The Trustees Of Columbia University In The City Of New York Methods and compositions for treatment of cardiac arrhythmia in non-human animals
WO2008060332A2 (en) 2006-06-02 2008-05-22 The Trustees Of Columbia University In The City Of New York Methods for treating or reducing muscle fatigue
WO2008021432A2 (en) 2006-08-17 2008-02-21 The Trustees Of Columbia University In The City Of New York Compositions and methods for treatment of conditions affecting the nervous system
WO2008021439A2 (en) * 2006-08-17 2008-02-21 The Trustees Of Columbia University In The City Of New York Compositions and methods for treatment of cardiac hypertrophy
WO2008064264A2 (en) 2006-11-20 2008-05-29 Armgo Pharma, Inc. In vivo methods for identifying and screening compounds that modulate calstabin binding to a ryanodine receptor
PL2250159T3 (pl) 2008-03-03 2012-05-31 Armgo Pharma Inc Sposób wytwarzania benzotiazepin z gamma-aminoalkilobenzenów
CN101891706B (zh) * 2010-04-09 2013-05-29 复旦大学 3,4-二氢苯并[f][1,4]噻氮杂*类化合物或其盐及其药物用途
WO2012019071A1 (en) 2010-08-06 2012-02-09 The Trustees Of Columbia University In The City Of New York Methods of preventing and treating sarcopenia
WO2012019076A1 (en) 2010-08-06 2012-02-09 The Trustees Of Columbia University In The City Of New York Compositions and methods for preventing and treating cardiac ischemia/reperfusion injury
WO2012037105A1 (en) 2010-09-14 2012-03-22 The Trustees Of Columbia University In The City Of New York Methods of treating, ameliorating or preventing stress-induced neuronal disorders and diseases

Also Published As

Publication number Publication date
TW201345900A (zh) 2013-11-16
SI2653466T1 (sl) 2015-03-31
ES2529890T8 (es) 2015-08-24
CO7091184A2 (es) 2014-10-21
KR101731459B1 (ko) 2017-04-28
EA201401141A8 (ru) 2015-08-31
HRP20141113T8 (hr) 2015-11-06
GT201400222A (es) 2018-09-28
CN104350045A (zh) 2015-02-11
CU24327B1 (es) 2018-03-13
CR20140476A (es) 2014-12-02
EP2653466A1 (en) 2013-10-23
ES2529890T3 (es) 2015-02-25
SG11201406404YA (en) 2014-11-27
RU2014145939A (ru) 2016-06-10
RU2644350C2 (ru) 2018-02-09
AP3591A (en) 2016-02-15
EP2653466B1 (en) 2014-10-29
PE20142193A1 (es) 2014-12-31
CL2014002756A1 (es) 2015-06-12
DK2653466T3 (en) 2015-02-02
EA027922B1 (ru) 2017-09-29
HK1192537A1 (zh) 2014-08-22
DOP2014000230A (es) 2014-12-15
MD20140119A2 (ro) 2015-04-30
HRP20141113T1 (hr) 2015-01-02
ZA201407499B (en) 2015-12-23
PH12014502256B1 (en) 2015-02-09
CU20140119A7 (es) 2015-03-30
NZ701122A (en) 2016-07-29
CA2870599A1 (en) 2013-10-24
TN2014000424A1 (fr) 2016-03-30
HK1207073A1 (zh) 2016-01-22
AR090712A1 (es) 2014-12-03
NI201400123A (es) 2015-03-05
CA2870599C (en) 2016-08-16
US20140378437A1 (en) 2014-12-25
US20130281512A1 (en) 2013-10-24
UA113759C2 (xx) 2017-03-10
JP2015514736A (ja) 2015-05-21
KR20150003347A (ko) 2015-01-08
PH12014502256A1 (en) 2015-02-09
MX350890B (es) 2017-09-25
SA113340479B1 (ar) 2015-09-03
EA201401141A1 (ru) 2015-04-30
HUE024284T2 (en) 2016-01-28
AU2013248313A1 (en) 2014-10-30
MD4489B1 (ro) 2017-06-30
MD4489C1 (ro) 2018-01-31
RS53711B1 (en) 2015-04-30
BR112014025670B1 (pt) 2020-06-30
EP2708535A1 (en) 2014-03-19
MA37525A1 (fr) 2016-05-31
PL2653466T3 (pl) 2015-04-30
US20140088171A1 (en) 2014-03-27
MX2014012575A (es) 2015-07-06
ME01969B (me) 2015-05-20
AU2013248313B2 (en) 2016-11-10
CN104350045B (zh) 2016-08-24
MA37525B1 (fr) 2016-12-30
TWI507399B (zh) 2015-11-11
JO3070B1 (ar) 2017-03-15
MY167783A (en) 2018-09-25
UY34742A (es) 2013-11-29
ECSP14027564A (es) 2015-08-31
WO2013156505A1 (en) 2013-10-24
IL235043A (en) 2016-10-31
JP5965542B2 (ja) 2016-08-10
AP2014008011A0 (en) 2014-10-31
PT2653466E (pt) 2014-12-03
US8853198B2 (en) 2014-10-07

Similar Documents

Publication Publication Date Title
CY1115826T1 (el) Μεσα για τη θεραπεια διαταραχων οι οποιες εμπλεκουν τη ρυθμιση των υποδοχεων ρυανοδινης
CY1120338T1 (el) Εκλεκτικοι ρυθμιστες υποδοχεα φωσφορικης σφιγγοσινης 1 και μεθοδοι χειρομορφικης συνθεσης
CY1121170T1 (el) Νεες ενωσεις ως ρυθμιστες πρωτεϊνικων κινασων
CY1125436T1 (el) Αναστολεις dna-pk
CY1123625T1 (el) Συνθεσεις και μεθοδοι για θεραπεια διαταραχων χρησης αλκοολης, πονου και αλλων ασθενειων
CY1120258T1 (el) Ενωσεις ετεροδικυκλο-υποκατεστημενης-[1,2,4]τριαζολο [1,5-c]κιναζολιν-5-αμινης καταλληλες για αγωγη ή προληψη διαταραχων του κεντρικου νευρικου συστηματος
CY1123059T1 (el) Αναστολη του διαυλου ιοντων παροδικου δυναμικου του υποδοχεα α1
CY1119707T1 (el) Ενωσεις διαρυλικου αμιδιου ως αναστολεις της κινασης
CY1119766T1 (el) Νεοι ρυθμιστες κινασης βενζοπυρανιου
CY1124828T1 (el) Αλλοστερικοι διαμορφωτες των νικοτινικων υποδοχεων ακετυλχολινης
CY1113665T1 (el) Θετικοι αλλοστερικοι ρυθμιστες του υποδοχεα μ1 με αρυλομεθυλο βενζοκιναζολινονη
ECSP10010230A (es) Derivados de isoxazolo-piridina
CY1120846T1 (el) 2-αμινο-6-(διφθορομεθυλ)-5,5-διφθορο-6-φαινυλ-3,4,5,6-τετραϋδροπυριδινες ως αναστολεις bace1
CY1120881T1 (el) Ανταγωνιστες υποδοχεα 5-ητ3
CY1118365T1 (el) Διαμορφωτες διυδροπυραζολης του gpr40
EA201071245A1 (ru) Новые терапевтические подходы для лечения болезни альцгеймера и связанных нарушений посредством модулирования реакции клеток на стресс
CY1113980T1 (el) Νεες θεραπευτικες μεθοδευσεις για θεραπευτικη αγωγη cmt και συναφων διαταραχων
NZ737399A (en) Ccr2 modulators
CY1122017T1 (el) Υποκατεστημενες ενωσεις χρωμανης ως ρυθμιστες του υποδοχεα ανιχνευτη ασβεστιου
EA201171063A1 (ru) Фармацевтические составы олмесартана
CY1119800T1 (el) Συνδυασμοι υποδοχεα της 5-ητ4 και αναστολεων ακετυλοχολινεστερασης για τη θεραπεια γνωστικων διαταραχων
BR112015010791A2 (pt) moduladores de gpr40 de di-hidropirazol
CY1117706T1 (el) Παραγωγα οξαζολινης και ισοξαζολινης ως ρυθμιστες crac
CY1121898T1 (el) Ενωσεις αμιδιου ως αγωνιστες tου υποδοχεα 5-ht4
CL2020002275A1 (es) Compuestos diólicos de aminopirazina como inhibidores de pi3k-y.